In the after-hours trading session on Wednesday, shares of Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) recovered on the US stock charts, increasing by 7.99% to $3.23. The stock closed at $2.99 after a sharp 11.01% drop during the regular session, which was followed by this comeback. The after-market resurgence came in response to a pivotal presentation delivered during the Congenital, Structural, and Valvular Heart Disease Interventions (CSI) 2025 Meeting held on Wednesday.
Clinical Insights into AVIM Therapy Unveiled
Orchestra BioMed presented fresh evidence at the CSI 2025 conference that supports the use of their exclusive Atrioventricular Interval Modulation (AVIM) therapy to treat high-risk hypertension.
The potential of AVIM therapy to treat hypertensive heart disease—a serious but little-known cardiovascular condition that is common in older adults with chronic hypertension—was highlighted in a presentation by Dr. Daniel Burkhoff, Director of the Cardiovascular Research Foundation’s Heart Failure, Hemodynamics, and Mechanical Circulatory Support Research.
Targeting an Underserved and High-Risk Population
Poorly controlled high blood pressure for an extended period of time increases the risk of adverse cardiac events, including myocardial infarction, stroke, and eventually heart failure. Hypertensive heart disease is the name given to this ailment.
Based on the clinical insights presented, AVIM treatment provides a new device-based solution specifically designed for these individuals. It does this by utilizing a special mechanism of action that lowers cardiac preload and alters the activity of the autonomic nervous system, both of which improve cardiovascular health.
Opening the Door to a Revolution
In his presentation, “Atrioventricular Interval Modulation (AVIM) Therapy for Hypertension and HFpEF,” Dr. Burkhoff presented AVIM therapy as a promising development in the treatment of hypertension. AVIM is a programmable solution that is intended to improve results for a subset of patients who are often underserved by traditional therapy. It is designed to effortlessly integrate with existing pacemaker and electrophysiology systems.
The therapy’s clinical significance and commercial prospects are further highlighted by regulatory bodies’ recent classification of it as a Breakthrough Device (BDD). The enthusiastic response to Orchestra BioMed’s attendance at CSI Frankfurt suggests that AVIM is becoming more and more popular as a game-changing tool for treating high-risk hypertension disorders.
